The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis

International Journal of Pancreatology

Volumn 23, Issue 2, 1998, Pages 83-100

  Bramhall, Simon R ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic pancreatitis; Differentiation; Molecular biology; Pancreatic cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; SCATTER FACTOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; ASPIRATION CYTOLOGY; CHRONIC PANCREATITIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE MUTATION; HIGH RISK POPULATION; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTO ONCOGENE; SCREENING TEST; TUMOR SUPPRESSOR GENE;

EID: 0031842176     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:23:2:83     Document Type: Article

References (195)

1. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995; 82: 111-115.
2. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7: 66-86.
3. Kocjan G, Rode J, Lees WR. Percutaneous fine needle aspiration cytology of the pancreas: advantages and pitfalls. J Clin Pathol 1989; 42: 341-347.
4. Rodriguez J, Kasberg C, Nipper M, Schoolar J, Riggs MW, Dyck WP. CT-guided needle biopsy of the pancreas: a retrospective analysis of diagnostic accuracy [see comments]. Am J Gastroenterol 1992; 87: 1610-1613.
5. Hyoty MK, Mattila JJ, Salo K, Nordback IH. Intraoperative fine needle aspiration cytologic examination of pancreatic lesions. Surg Gynecol Obstet 1991; 173: 193-197.
6. Earnhardt RC, McQuone SJ, Minasi JS, Feldman PS, Jones RS, Hanks JB. Intraoperative fine needle aspiration of pancreatic and extrahepatic biliary masses. Surg Gynecol Obstet 1993; 177: 147-152.
7. Jennings PE, Coral A, Donald JJ, Rode J, Lees WR. Ultrasound-guided core biopsy. Lancet 1989; 1: 1369-1371.
8. Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161: 26-29.
9. Endo YM, Tamura H, Okuda S. Cytodiagnosis of pancreatic malignant tumours by aspiration under direct vision using a duodenal fibrescope. Gastroenterology 1974; 67: 944-951.
10. Farini R, Nitti D, Favero GD, Rossi CR, Constantin G, Rebuffi A. CEA concentration and cytology in duodenal fluid collected during the secretin-pancreozymin test. Hepatogastroenterology 1985; 27: 213-216.
11. Tatsuta M, Yamamura H, Yamamoto R, Okano Y, Morii T, Okuda S. Values of CA19-9 in the serum, pure pancreatic juice and aspirated pancreatic material in the diagnosis of malignant pancreatic tumour. Cancer 1985; 56: 2669-2673.
12. Ryan ME. Cytologic brushings of ductal lesions during ERCP. Gastrointest Endosc 1991; 37: 139-142.
13. Kemeya S, Kuno N, Kasugai T. The diagnosis of pancreatic cancer by pancreatic juice cytology. Acta Cytol 1981; 25: 354-360.
14. Hatfield ARW, Smithies A, Wilkins R, Levi AJ. Assessment of ERCP and pure pancreatic juice cytology in patients with pancreatic diseases. Gut 1976; 17: 14-21.
15. Kasugai T, Kobayashi S, Kuno N. Endoscopic cytology of the oesophagus, stomach and pancreas. Acta Cytol 1978; 22: 327-330.
16. Kawanishi H, Pollard HW. Endoscopic evaluation of cancer of the pancreas. Semin Oncol 1979; 6: 306-317.
17. Goodale RL, Gajl-peczalaka K, Dressel T, Samuelson J. Cytological studies for the diagnosis of pancreatic cancer. Cancer 1981; 47: 1652-1655.
18. Bodner E, Schamberger K, Mikuz G. Cytological diagnosis of pancreatic tumours. World J Surg 1982; 6: 103-106.
19. Mitchell ML, Carney CN. Cytological criteria for the diagnosis of pancreatic carcinoma. Am J Clin Pathol 1985; 82: 171-176.
20. Nakaizumi A, Tatsuta M, Uehara H, Yamamoto R, Takenaka A, Kishigami Y, Takemura K, Kitamura T, Okuda S. Cytologic examination of pure pancreatic juice in the diagnosis of pancreatic carcinoma. The endoscopic retrograde intraductal catheter aspiration cytologic technique. Cancer 1992; 70: 2610-2614.
21. Klein G, Klein E. Evolution of tumours and the impact of molecular oncology. Nature 1985; 315: 190-195.
22. Lemoine NR, Hall PA. Growth factors and oncogenes in pancreatic cancer. Clin Gastroenterol 1990; 4: 815-832.
23. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
24. Shibata D, Capella G, Perucho M. Mutational activation of the c-Ki-ras gene in human pancreatic carcinoma. Bailliere's Clin Gastroenterol 1990; 4: 151-169.
25. Scarpa A, Capelli P, Villaneuva A, Zamboni G, Lluis F, Accolla R, Mariuzzi G, Capella G. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer 1994; 57: 167-171.
26. Almoguero C, Shibata D, Forreseter K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
27. Smit VT, Boot AJ, Smits AA, Fleuran GJ, Cornelisse CJ, Bos JL. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16: 7773-7782.
28. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JW, Bartram CR. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989; 43: 1037-1041.
29. Mariyama M, Kishi K, Nakamura K, Obata H, Nishimura S. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn J Cancer Res 1989; 80: 622-626.
30. Gonzalez-Cadavid NF, Zhou D, Battifora H, Bar-Eli M, Cline MJ. Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. Oncogene 1989; 4: 1137-1140.
31. Tada M, Yokosuka O, Omata M, Ohto M, Isono K. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990; 66: 930-935.
32. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K, Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 1991; 6: 857-862.
33. Montijima K, Tsunoda T, Kanematsu T. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten ras oncogene. Ann Surg 1991; 214: 657-662.
34. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102: 230-236.
35. Tabata T, Fujimori T, Maeda S, Yamamoto M, Saitoh Y. The role of Ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int J Pancreatol 1993; 14: 237-244.
36. Hruban RH, van-Mansfeld AD, Offerhaus GJ, van-Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-554.
37. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560.
38. Schaeffer BK, Glasner S, Kuhlmann E, Myles JL, Longnecker DS. Mutated c-K-ras in small pancreatic adenocarcinomas. Pancreas 1994; 9: 161-165.
39. Pellegata NS, Losekoot M, Fodde R, Pugliese V, Saccomanno S, Renault B, Bernini LF, Ranzani GN. Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer. Anticancer Res 1992; 12: 1731-1736.
40. Montijima K, Urano T, Nagata Y, Shiku H, Tsurifune T, Kanematsu T. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic cancer. Ann Surg 1993; 217: 138-143.
41. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasia of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-956.
42. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976; 2: 1525-1536.
43. Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni JF. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol 1988; 128: 324-336.
44. Hirayama T. Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol 1989; 19: 208-215.
45. Fujii H, Egoni H, Chaney W, Pow P, Pelling J. Pancreatic ductal adenocarcinomas induced in Syrian hamsters by N-nitrosobis(2-oxopropyl)amine contain a c-K-ras oncogene with a point-mutated codon 12. Mol Carcinogenesis 1990; 3: 296-300.
46. Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki K. Point mutation of K-ras gene codon 12 in biliary tract tumours. Gastroenterology 1994; 107: 1147-1153.
47. Masson P, Andren-Sandberg A. Crude isolation of DNA from unselected human pancreatic tissue and amplification by the polymerase chain reaction of Ki-ras oncogene to detect point mutations in pancreatic cancer. Acta Oncologica 1992; 31: 421-424.
48. Satoh K, Sawai T, Shimosegawa T, Koizumi M, Yamazaki T, Mochizuki F, Toyota T. The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas. Int J Pancreatol 1993; 14: 135-143.
49. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ. Multiple K-ras codon mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51: 3497-3502.
50. Yashimo T, Fulton N, Hara H. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumours. Surg 1993; 114: 758-764.
51. Tada M, Omata M, Ohto M. Ras gene mutations in intraductal papillary neoplasms of the pancreas. Analysis in five cases. Cancer 1991; 67: 634-637.
52. Cerny WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992; 52: 4507-4513.
53. DiGiuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, van-den-Berg FM, Cameron JL, van-Mansfeld AD. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994; 144: 889-895.
54. Scarpa A, Zamboni G. Genetic abnormalities in periampullary cancer, in Pancreatic Cancer: Molecular and Clinical Advances, Neoptolemos, JP, Lemoine, NR, eds. Blackwell Scientific, Oxford 1995.
55. Van-Laethem J-L, Vertongen P, Deviere J, Van-Rampelbergh J, Rickaert F, Cremer M, Robberecht P. Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut 1995; 36: 781-787.
56. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-3573.
57. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, DiMagno EP, Andren-Sandberg A, Domellof L, Group IPS. Pancreatitis and the risk of pancreatic cancer. N Eng J Med 1993; 328: 1433-1437.
58. Daus H, Trumper L, Burger B. Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas. Deutsche Medizinische Wochenschrift 1995; 120: 821-825.
59. Riou G, Barrios M, Le MG, George M, Le Doussal V, Haie C. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet 1987: 1: 761-763.
60. Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD, Brinster RL. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci USA 1991; 88: 93-97.
61. Yamada H, Sakamoto H, Taira M, Nishimura S, Shimosato Y, Terada M, Sugimura T. Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes. Jpn J Cancer Res 1986; 77: 370-375.
62. Wakita K, Ohyanagi H, Yamamoto K, Tokuhisa T, Saitoh Y. Overexpression of c-Ki-ras and c-fos in human pancreatic carcinomas. Int J Pancreatol 1992; 11: 43-47.
63. Slamon DJ, deKernion JB, Verma IM, Cline MJ. Expression of cellular oncogenes in human malignancies. Science 1984; 224: 256-262.
64. Ullrich A, Coussens L, Hayflick JS. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-425.
65. Chen YF, Pan GZ, Hou X, Liu TH, Chen J, Yanaihara C, Yanaihara N. Epidermal growth factor and its receptors in human pancreatic carcinoma. Pancreas 1990; 5: 278-283.
66. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992; 166: 7-12.
67. Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 1986; 83: 5141-5144.
68. Korc M, Chandrasekar B, Shah GN. Differential binding and biological activities of epidermal growth factor and transforming growth factor alpha in a human pancreatic cancer cell line, pt. 1. Cancer Res 1991; 51: 6243-6249.
69. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transform ing growth factor alpha. J Clin Invest 1992; 90: 1352-1360.
70. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991; 163: 111-116.
71. Wright NA, Poulsom R, Stamp GW, Hall PA, Jeffery RE, Longcroft JM, Rio MC, Tomasetto C, Chambon P. Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol 1990; 162: 279-284.
72. Korc M, Freiss H, Yamanaka Y, Kobrin MS, Buchler M, Beger HG. Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma. Gut 1994; 35: 1468-1473.
73. Jaskiewicz K, Krige JE, Thomson J. Expression of p53 tumor suppressor gene, oncoprotein c-erb-B2, cellular proliferation and differentiation in malignant and benign pancreatic lesions. Anticancer Res 1994; 14: 1919-1922.
74. Logsdon CD, Keyes L, Beauchamp RD. Transforming growth factor-β (TGF-β1) inhibits pancreatic acinar cell growth. Am J Physiol 1992; 262: 364-368.
75. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors 1993; 8: 23-34.
76. Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, Baldwin RL, Korc M. Enhanced expression of the type II transforming growth factor β receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993; 53: 2704-2707.
77. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105: 1846-1856.
78. Castillo A, Prieto J, Fausto N. Transforming growth factor-α in chronic liver disease: effects of interferon alpha therapy. N Engl J Med 1991; 324: 933-940.
79. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990; 86: 453-462.
80. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor-β1 is present at sites of extracellular matrix expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991; 88: 6642-6646.
81. Van Laethem JL, Deviere J, Resibois A. Localisation of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis. Gastroenterology 1995; 108: 1873-1881.
82. Gress T, Muller-Pillasch F, Elasser HP. Enhancement of transforming growth factor beta 1 expression in the rat pancreas during regeneration from caerulein-induced pancreatitis. Eur J Clin Invest 1994; 24: 679-685.
83. Friess H, Yamanaka Y, Buchler M, Kobrin MS, Tahara E, Korc M. Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis. Int J Cancer 1994; 56: 668-674.
84. Tsutsumi M, Yasui W, Naito A, Ohashi K, Kobayashi E, Noguchi O, Horiguchi K, Okita S, Tsujiuchi T, Kitada H, et al. Expression of cripto in human pancreatic tumors. Jpn J Cancer Res 1994; 85: 118-121.
85. Riese DJ 2nd, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, Stern DF. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 1996; 12: 345-353.
86. Yokoyama M, Funatomi H, Kobrin MS, Ebert M, Friess H, Buchler MW, Korc M. Betacellulin, a member of the epidermal growth-factor family, is overexpressed in human pancreatic cancer. Int J Cancer 1995; 7: 825-829.
87. Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi 1992; 59: 51-61.
88. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR. The c-erb B2 proto-oncogene in human pancreatic cancer. J Pathol 1990; 161: 195-200.
89. Williams TM, Weiner DB, Greene MI, Maguire H, Jr. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 1991; 59: 46-52.
90. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, Beger HG, Korc M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993; 24: 1127-1134.
91. Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 1995; 17; 15-21.
92. Friess H, Yamanaka Y, Buchler M. A subgroup of patients with chronic pancreatitis overexpress the c-erb-B2 proto-oncogene. Ann Surg 1994; 220: 183-192.
93. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995; 1: 1413-1420.
94. Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, Gullick WJ, Kloppel G. The erbB-3 gene in human pancreatic cancer. J Pathol 1992; 168: 269-273.
95. Leung HY, Hughes CM, Kloppel G, Williamson RCN, Lemoine NR. Localisation of expression of fibroblast growth factors and their receptors in pancreatic adenocarcinoma by in-situ hybridisation. Int J Oncol 1994; 4: 1219-1223.
96. Beauchamp RD, Lyons RM, Yang EY, Coffey R Jr, Moses HL. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas 1990; 5: 369-380.
97. Friess H, Yamanaka Y, Buchler M. Increased expression of acidic and basic fibroblast growth factors in chronic pancreatitis. Am J Pathol 1994; 144: 117-128.
98. Humbel RE. Insulin-like growth factors I and II. Eur J Biochem 1990; 190: 445-462.
99. Daughaday W. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumours. Endocrinology 1990; 127: 1-4.
100. Massague J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem 1982; 257: 5038-5045.
101. Baxter RC, Martin JL. Binding proteins for the insulin-like growth factors: structure, regulation and function. Progr Growth Fact Res 1989; 1: 49-68.
102. Blum WF, Jenne EW, Kietzmann K, Ranke MB, Bierich JR. Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 1989; 125: 766-772.
103. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, Bell GI, Shows TB. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986; 46: 6169-6173.
104. El-Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994; 57: 491-497.
105. Mossner J, Logsdon CD, Goldfine ID, Williams JA. Do insulin and the insulin like growth factors (IGFs) stimulate growth of the exocrine pancreas? Gut 1987; 28: 51-55.
106. Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T, Shizume K. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 1990; 50: 103-107.
107. Basso D, Plebani M, Fogar P. Insulin-like growth factor-I alpha and beta in pancreatic cancer: role in tumor invasiveness and associated diabetes. Int J Clin Lab Res 1995; 25: 40-43.
108. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007-2011.
109. Montesano R, Matsumoto K, Nakamura T. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67: 901-908.
110. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 29-33.
111. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990; 111: 2097-2108.
112. Ebert M, Yokoyama M, Friess H, Buchler M, Korc M. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994; 54: 5775-5778.
113. Reich NC, Levine AJ. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 1984; 308: 199-201.
114. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RCG, Neoptolemos J, Williamson RCN, Lane DP, Lemoine NR. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-1082.
115. Redston MS, Caldas C, Seymour AB, Hruban RH, da-Costa L, Yeo CJ, Kern SE. P53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033.
116. Kalthoff H, Schmidt A, Roeder C, Schmeigel W. Alterations of p53 in benign lesions outnumber those in their malignant counterpart. Int J Pancreatol 1993; 14: 92.
117. Kalthoff H, Schmiegel W, Roeder C. P53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289-293.
118. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, Wood M, Obara T, Heath CW, Lynch H. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer 1996; 79: 700-716.
119. Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992; 7: 1503-1511.
120. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-1543.
121. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, Beger HG, Korc M. P53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69: 151-160.
122. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H, Namiki M, Klein-Szanto AJP. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118: 150-154.
123. Neuman WL, Wasylyshyn ML, Jacoby R, Erroi F, Angriman I, Montag A, Brasitus T, Michelassi F, Westbrook CA. Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. Genes Chromosomes Cancer 1991; 3: 468-473.
124. Ding SF, Habib NA, Delhanty JD, Bowles L, Greco L, Wood C, Williamson RC, Dooley JS. Loss of heterozygosity on chromosomes 1 and 11 in carcinoma of the pancreas. Br J Cancer 1992; 65: 809-812.
125. Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond J, Wynford-Thomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogenesis 1993; 7: 83-88.
126. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253: 665-669.
127. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, Yanagisawa A, Tsuchiya E, Kato Y, Nakamura Y. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992; 52: 6696-6698.
128. Leung HY, Lemoine NR. Pancreatic cancer, in Cancer: A Molecular Approach, Lemoine N, Neoptolemos JP, Cooke T, eds. Blackwell Scientific; Oxford 1994; pp. 105-115.
129. McKie AB, Filipe MI, Lemoine NR. Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. Int J Cancer 1993; 55: 598-603.
130. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, Yeo CJ, Kern SE. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994; 54: 2761-2764.
131. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW, Vogelstein B. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247; 49-56.
132. Simon B, Weinel R, Hohne M, Watz J, Schmidt J, Kortner G, Arnold R. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology 1994; 106: 1645-1651.
133. Hohne MW, Halatsch ME, Kahl GF, Weinel RJ. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992; 52: 2616-2619.
134. Hahn SA, Seymour AB, Shamsul Hoque ATM, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995; 55: 4670-4675.
135. Barton CM, McKie AB, Hogg A, Bia B, Elia G, Phillips SM, Ding SF, Lemoine NR. Abnormalities of the RB1 and DCC tumor suppressor genes: uncommon in human pancreatic adenocarcinoma. Mol Carcinogenesis 1995; 13: 61-69.
136. Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
137. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. Cancer Res 1996; 56: 2527-2530.
138. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genet 1996; 13: 343-346.
139. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996; 383: 832-836.
140. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, Carlson M, Joslyn G, Groden J, White R, Miki Y, Miyoshi Y, Nishisho I, Nakamura Y. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991; 251: 1366-1370.
141. Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau JH, Raskind WH, Haggitt RC, Reid BJ, Meltzer SJ. Loss of heterozygosity involving the MCC and APC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA 1992; 89: 3385-3388.
142. D'Amico D, Carbone DP, Johnson BE, Meltzer SJ, Minna JD. Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. Cancer Res 1992; 52: 1996-1999.
143. Lee W-H, Bookstein R, Hong F, Young L-J, Shew J-Y, Lee EY-HP. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235: 1394-1399.
144. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJ. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992; 7: 1503-1511.
145. Huang L, Lang D, Geradts J, Obara T, Klein-Szanto AJ, Lynch HT, Ruggeri BA. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol Carcinogenesis 1996; 15: 85-95.
146. Wooster R, Neuhasen SL, Mangion J, et al. Localisation of a breast cancer susceptibility gene BRCA to chromosome 13q12-13. Science 1994; 265: 2088-2090.
147. Schutte M, da Costa LT, Hahn SA, Moskaluk C, Shamsul Hoque ATM, Rozenblum E, Weinstein CL, Bittner M, Meltzer PS, Trent JM, Yeo CJ, Hruban RH, Kern SE. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 1995; 92: 5950-5954.
148. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364.
149. Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst 1991; 83: 281-285.
150. Nakamori S, Ishikawa O, Ohhigashi H, Kameyama M, Furukawa H, Sasaki Y, Inaji H, Higashiya M, Imaoka A, Iwanaga T, Funai H, Wada A, Kimura N. Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion. Clin Exp Metastasis 1993; 11: 151-158.
151. Nakamori S, Ishikawa O, Ohigashi H, Imaoka S, Sasaki Y, Kameyama M, Kabuto T, Furukawa H, Iwanakga T, Kimura N. Clinicopathological features and prognostic significance of nucleoside diphosphate kinase/nm23 gene product in human pancreatic exocrine neoplasms. Int J Pancreatol 1993; 14: 125-133.
152. Cannon-Albright LA. Assignment of a loscus for familial melanoma MLM, to chromosome 9p13-p22. Science 1992; 258: 1148-1152.
153. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
154. Caldas C, Hahn SA, Da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994; 8: 27-32.
155. Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJ, Chang H, Ruggeri BA. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996; 56: 1137-1141.
156. Johansson B, Bardi G, Heim S, Mandahl N, Andren-Sandberg A, Mitelman F. Cytogenetic analysis of pancreatic adenocarcinomas. Cancer Genet Cytogenet 1991; 52: 238,239.
157. Wasylyshyn ML, Neuman WL, Angriman I, Snyder LA, Montag AG, Westbrook CA, Michelassi F. Evidence for a new tumor-suppressor gene involved in gastrointestinal malignancies. Surgery 1991; 110: 265-268.
158. Bale AE, Norton JA, Wong EL, Fryburg JS, Maton PN, Oldfield EH, Streeten E, Aurbach GD, Brandi ML, Friedman E. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res 1991; 51: 1154-1157.
159. Teh BT, Hayward NK, Wilkinson S, Woods GM, Cameron D, Shepherd JJ. Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumours. Br J Cancer 1990; 62: 253,254.
160. Gerdes J, Lemke H, Baisch H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1717.
161. Prelich G, Tan CK, Kotsura M. Functional identity of proliferating nuclear cell antigen and a DNA polymerase-delta auxiliary protein. Nature 1987; 326; 517-520.
162. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfield AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988; 154: 184-192.
163. Jains S, Filipe MI, Hall PA, Wassem N, Lane DP, Levison DA. Prognostic value of proliferating nuclear antigen in gastric carcinoma. J Clin Pathol 1991; 44: 655-659.
164. Woods AL, Hall PA, Shepherd NA. The assessment of proliferating nuclear cell antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology 1991; 19: 21-27.
165. Ionov YM, Peinado A, Maikhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-561.
166. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819.
167. Han HJ, Yanagisawa A, Kato Y, Park JG, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993; 53: 5087-5089.
168. Cottam DW, Rees RC. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (review). Int J Oncol 1993; 2: 861-872.
169. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264: 17,374-17,378.
170. Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C. Structure and expression in breast tumours of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 1994; 54: 2091-2094.
171. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-113.
172. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
173. Burmer GC, Ravinovich PS, Loeb LA. Analysis of c-Ki-ras mutations in human colon cancer by cell sorting, polymerase chain reaction and DNA sequencing. Cancer Res 1989; 49: 2141-2146.
174. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancer by single strand conformation polymorphism analysis of the polymerase chain reaction. Oncogene 1990; 5: 1037-1043.
175. Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991; 100: 233-238.
176. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-2474.
177. Neville EM, Ellison G, Kiaris H. Detection of K-ras mutations in non-small cell lung carcinoma. Int J Oncol 1995; 7: 511-514.
178. Shibata D, Almoguera C, Forrester K, Dunitz J, Martin SE, Cosgrove MM, Perucho M, Arnheim N. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990; 50: 1279-1283.
179. Urban T, Ricci S, Grange JD, Lacave R, Boudghene F, Breittmayer F, Languille O, Roland J, Bernaudin JF. Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993; 85: 2008-2012.
180. Apple SK, Hecht JR, Novak JM, Nieberg RK, Rosenthal DL, Grody WW. Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 1996; 105: 321-326.
181. Trumper LH, Burger B, von-Bonin F, Hintze A, von-Blohn G, Pfreundschuh M, Daus H. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. Br J Cancer 1994; 70: 278-284.
182. Watanabe H, Sawabu N, Ohta H, Satomura Y, Yamakawa O. Motoo Y, Okai T, Takahashi H, Wakabayashi T. Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res, 1993; 84: 961-965.
183. Kondo H, Sugano K, Fukayama N, Kyogoku A, Nose H, Shimada K, Ohkura H, Ohtsu A, Yoshida S, Shimosato Y. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994; 73: 1589-1594.
184. Ihalainen J, Taavitsainen M, Salmivaara T, Palotie A. Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing. J Clin Pathol 1994; 47: 1082-1084.
185. Villaneuva A, Balart J, Reyes G. Detection of c-K-ras point mutations in fine needle aspirates of pancreatic masses. Int J Pancreatol 1993; 14: 91,92.
186. Miki H, Matsumoto S, Harada H, Mori S, Haba R, Ochi K, Kobayashi S, Ohmori M. Detection of c-Ki-ras point mutation from pancreatic juice. A useful diagnostic approach for pancreatic carcinoma. Int J Pancreatol 1993; 14: 145-148.
187. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-1229.
188. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994; 3: 67-71.
189. Bartek J, Iggo P, Gannopn J, Lane DP. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893-899.
190. Hall PA, Domizio P, Slavin G, Levison DA. Immunohistochemistry in district general hospitals in England and Wales. J Clin Pathol 1987; 40: 1306-1309.
191. Hall PA, Ray A, Lemoine NR, Midgley CA, Krautz T, Lane DP. P53 immunostaining as a marker of malignant disease in diagnostic cytopathology (letter). Lancet 1991; 338: 513.
192. Leroith D, Clemmons D, Nissley P, Rechler MM. Insulin-like growth factors in health and disease. Ann Intern Med 1992; 116: 854-862.
193. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. N Engl J Med 1994; 331: 81-84.
194. Everhart J, Wright D. Diabetes mellitus is a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273: 1605-1609.
195. Permert J, Larsson J, Westermark GT, Herrington MK, Christmanson L, Pour PM, Westermark P, Adrian TE. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330: 313-318.